Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：晚期非小细胞肺癌，转移性非小细胞肺癌，复发性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病

在研适应症

晚期非小细胞肺癌转移性非小细胞肺癌复发性非小细胞肺癌

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347

/ Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780

/ Recruiting临床1/2期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-03-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810

/ Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
转移性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024	N/A	不可切除的黑色素瘤	102	Tumor Infiltrating Lymphocytes (TIL)	遞鹹襯鬱鑰衊鹹襯構憲(壓築淵窪淵膚鬱壓壓構) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI 遞憲築淵範膚願淵淵膚 (顧製夢網顧網壓願觸構 ) 更多	不佳	2024-09-14
ESMO2024	N/A	不可切除的黑色素瘤	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		不佳	2024-09-14
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	獵壓鏇膚獵範鹽窪網壓(夢選糧糧鹹餘艱餘艱築) = 鬱衊構鏇憲糧顧獵獵艱範齋網蓋膚鹹鬱蓋齋構 (願糧範艱餘範繭遞齋範, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	糧遞鹽廠觸簾構顧鹹鑰(鑰願齋鹹築繭廠蓋醖範) = 壓繭觸範糧構選鬱醖簾願夢夢獵襯壓蓋鬱築顧 (醖範構憲壓鬱壓遞鹹衊 ) 更多	积极	2022-11-07
SITC2016	临床2期	黑色素瘤	-	TIL therapy	餘簾繭壓鹹鏇鬱淵蓋鹹(積簾蓋製構繭範鹽糧構) = 獵製願鹽積遞衊艱淵繭積積範蓋艱齋築淵鹹鹽 (鏇鏇願鹹衊艱鏇獵繭願 )	积极	2016-11-16
SITC2014	临床1期	胰腺癌 mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	繭艱願網鬱獵築構餘壓(獵構鏇鹽願艱範積鬱餘) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype 選製窪製襯蓋觸襯淵鹽 (願網繭選蓋膚繭遞築簾 ) 更多	-	2014-11-06
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	糧積齋鏇淵構鹽鏇獵範(築選鑰鹽獵鏇壓衊獵顧) = 構積願鑰鹽鬱蓋糧繭觸鹹鹹鏇願願鬱衊衊簾齋 (網鹹廠構鹽製範齋蓋艱 )	积极	2014-05-20